oxidopamine has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 1 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lafreniere, MA | 1 |
Powdrill, MH | 1 |
Singaravelu, R | 1 |
Pezacki, JP | 1 |
1 other study available for oxidopamine and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
Article | Year |
---|---|
6-Hydroxydopamine Inhibits the Hepatitis C Virus through Alkylation of Host and Viral Proteins and the Induction of Oxidative Stress.
Topics: Alkylation; Antiviral Agents; Cell Line, Tumor; Cell Proliferation; Hepacivirus; Hepatitis C; Humans | 2016 |